Pfizer's PAXLOVID Study: Real-World Insights on COVID-19 Treatment
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a study titled 'Post Marketing Surveillance to Observe Safety and Effectiveness of PAXLOVID in Patients With Positive Results of Viral Testing, and Who Are at High Risk for Progression to Severe COVID-19.' The study aims to assess the real-world safety and effectiveness of PAXLOVID in patients at high risk of severe COVID-19, particularly in Korea. This is significant as it provides insights into the drug's performance outside controlled clinical settings.
The intervention being tested is PAXLOVID, an antiviral treatment intended to reduce the severity of COVID-19 in high-risk patients. The study focuses on patients who have tested positive for the virus and are at risk of severe outcomes, including hospitalization or death.
This observational study follows a case-only model and does not involve any specific allocation or masking. The primary purpose is to gather real-world data on PAXLOVID's effectiveness and safety over a 28-day follow-up period after treatment.
The study began on November 29, 2023, with its primary completion and estimated study completion dates yet to be announced. The last update was submitted on July 22, 2025, highlighting ongoing data collection and analysis.
Market implications of this study are significant for Pfizer's stock performance as positive real-world data could bolster investor confidence and market position against competitors. The study's outcomes may influence healthcare providers' decisions and potentially increase PAXLOVID's market share.
The study is currently recruiting, with further details available on the ClinicalTrials portal.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
37 minutes ago
- Globe and Mail
AbbVie's Phase 3 Study on Telisotuzumab Vedotin: A Potential Game-Changer in NSCLC Treatment
Abbvie ((ABBV)), Abbvie (($CC: announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AbbVie is conducting a Phase 3 clinical study titled 'A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer'. The study aims to evaluate the efficacy and safety of telisotuzumab vedotin compared to docetaxel in treating non-squamous non-small cell lung cancer (NSCLC) in adults who have undergone prior treatment. The study tests two interventions: telisotuzumab vedotin, an investigational biological drug administered intravenously every two weeks, and docetaxel, an active comparator drug given intravenously every three weeks. The goal is to determine which treatment better reduces disease activity and manages adverse events. This interventional study employs a randomized, parallel assignment model without masking, focusing primarily on treatment. Participants are randomly assigned to receive either telisotuzumab vedotin or docetaxel, with approximately 698 participants expected to be enrolled globally. The study began on March 25, 2022, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 22, 2025, indicating ongoing recruitment and study progress. For investors, this study could significantly impact AbbVie's stock performance and investor sentiment, especially if telisotuzumab vedotin demonstrates superior efficacy and safety. Success in this trial could position AbbVie favorably against competitors in the NSCLC treatment market. The study is ongoing, and further details are available on the ClinicalTrials portal.
Globe and Mail
an hour ago
- Globe and Mail
AstraZeneca's Latest Study: Evaluating Ceralasertib's Impact on Cancer Drug Pharmacokinetics
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical study titled 'A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Ceralasertib on Pharmacokinetics of Drug X, Drug Y and Drug Z in Participants With Advanced Solid Tumours.' The study aims to assess how ceralasertib affects the pharmacokinetics of three other drugs in patients with advanced solid tumors, potentially offering new insights into cancer treatment. The intervention involves administering ceralasertib, alongside Drugs X, Y, and Z. Ceralasertib is given twice daily over a week, with single doses of the other drugs administered on specific days to evaluate interactions. This open-label study follows a single-group assignment model with no masking, focusing on treatment as its primary purpose. It includes multiple visits and wash-out periods to ensure accurate results. The study began on May 21, 2025, with the latest update submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring transparency. For investors, this study could influence AstraZeneca's stock performance by potentially expanding its oncology portfolio. The collaboration with Parexel highlights a strategic partnership that could enhance research capabilities, impacting investor sentiment positively. Competitors in the oncology sector may also be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.
CTV News
2 hours ago
- CTV News
Manitoba reaches settlement with family of woman who died after halted medical flight
An empty bed is seen at a hospital in Sarnia, Ont., on Wednesday, January 26, 2022. THE CANADIAN PRESS/Chris Young WINNIPEG — The Manitoba government says it has settled a lawsuit with the family of a woman who died during the COVID-19 pandemic while in the process of being transferred out of province due to a shortage of hospital beds. Matt Wiebe, minister of justice and the province's attorney general, confirmed a settlement was recently reached with the family of Krystal Mousseau more than two years after Mousseau's mother first sued the provincial government and health agencies. Elaine Mousseau alleged that cuts to health care and improper medical decisions contributed to her daughter's death in May 2021. Mousseau was in intensive care with severe COVID-19 pneumonia and died after being taken by ambulance to a waiting airplane that was to take her to Ottawa. Details of the settlement were not made available. Wiebe says he is pleased the province has been able to reach an agreement with the Mousseau family. 'While it can't bring back their loved one or repair the harms done to their family, we hope this agreement brings them clarity and a sense of closure,' Wiebe said in a statement on Friday. 'Our government remains committed to rebuilding health care in northern Manitoba and across our province.' Mousseau died on May 25, 2021, after an aborted attempt to fly her from an intensive care unit in Brandon, Man., to a hospital in Ottawa. The province, under the previous Progressive Conservative government, sent dozens of intensive-care patients to other provinces that spring due to a shortage of beds as COVID-19 cases rose and hospitals struggled to deal with an influx of people needing care. Elaine Mousseau alleged that the government and Shared Health, the provincial body that co-ordinates many health services, failed to provide proper care. Shared Health said on Friday that any settlement is confidential in nature and it would not be commenting on the matter. Elaine Mousseau's lawyer was not immediately made available to comment on the settlement. A letter from the regional authority in western Manitoba to the family shortly after Krystal Mousseau's death, which was released publicly, said the transport team did not have a piece of equipment that would let them constantly monitor Mousseau's blood pressure, so a blood-pressure cuff was used instead. Mousseau was also being given at least one medication at the wrong rate, the letter stated. The lawsuit alleged the Tory government ignored warnings in 2019 when it privatized some air ambulance services. The government also created a scenario where hospitals couldn't deal with an influx of patients when it reduced the number of critical care beds in 2019, the lawsuit claimed. The statement of claim also alleged staff at the hospital allowed Mousseau to leave while she was in unstable condition and at severe risk. Mousseau showed high blood pressure and a sudden elevated heart rate shortly before she was put into the ambulance on the way to the airport, the statement of claim alleged. She went into cardiac arrest while in the ambulance, was sent back to hospital, and suffered another cardiac arrest and multiple organ failure before being pronounced dead the next day, the document said. This report by The Canadian Press was first published July 25, 2025. Brittany Hobson, The Canadian Press
